UroGen Pharma Ltd. (URGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN) investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN UROGEN PHARMA LTD. (URGN), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [e-mail], by telephone at [phone] or visit our website at www.howardsmithlaw.com.

What Happened?

On May 16, 2025, the U.S. Food and Drug Administration (“FDA”) published materials in advance of its Advisory Committee meeting regarding UroGen’s drug application for its experimental bladder cancer therapy, UGN-102. The FDA questioned the efficacy and utility of UGN-102. Specifically, the FDA stated that it “does not agree with the statement that the complete response rate for UGN-102 was higher or more durable than that for Transurethral resection of bladder tumor (TURBT)” and that the Company’s claims that UGN-102 may “reduce the burden of repeated TURBTs” lacks long-term data and is unclear.

On this news, UroGen’s stock price fell $2.54, or 25.8%, to close at $7.31 per share on May 16, 2025, thereby injuring investors.

Contact Us To Participate or Learn More:

If you purchased UroGen securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: [phone]
Email: [e-mail],
Visit our website at: www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.